Rita Nanda MD

Breast Cancer, Hematologic Oncology

University of Chicago Medicine

5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Fax+1 773-834-2484

Dr. Nanda is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nanda's full profile Already have an account?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2005
University of ChicagoResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Massachusetts Institute of TechnologyB.S., Chemical Engineering, 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2000 - 2029
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
TERMINATED
PHASE2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
RECRUITING
PHASE2
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
COMPLETED
PHASE1

Publications & Presentations

PubMed

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Claudine Isaacs, Rita Nanda, Christina Yau, A Jo Chien, Dawn L Hershman
JAMA Oncology. 2026-07-30
1 citations
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Emily Ly, Frederick M Howard, Nan Chen, Olwen Hahn, Gini F Fleming
Journal of Oncology Pharmacy Practice. 2026-06-01
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.
Maeve A Hennessy, Elizabeth Terman, Damé Idossa, Alexis LeVee, Roberto A Leon-Ferre
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2026-06-01

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study
M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer
Saha P and Nanda R, Oncology and Hematology Review, 1/8/2016

Books/Book Chapters

Cancer Biology Review: A Case Based Approach
Chapter: Fundamental of DNA Damage and Repair
P Connell and R NandaEditors: W Stadler.Edition 1st,2013
Cancer Medicine
Chapter: Recurring Chromosome Rearrangements in Human Cancer
DA Levitan, R Nanda, JD Rowley, OI OlopadeEditors: J Holland and E Frei.Edition 6th,2003
Pocket Primary Care
Chapter: Chronic Fatigue Syndrome
Nanda REditors: LK Halasyamani and BP Lucas.Edition 1st,2001

Lectures

Advances in Triple-Negative Breast Cancer
Cancun, Mexico - 1/1/2016
Immunotherapy for the Treatment of Triple-Negative Breast Cancer
Royal College of Physicians, London, United Kingdom - 1/1/2016
Immunotherapy in Oncology
Cancun, Mexico - 1/1/2016

Other

Immunotherapy for triple-negative breast cancer
Numerous Outlets
1/1/2016
Interview on the role of clinical trials for breast cancer
WebMD
1/1/2013
Interview on treatment and research for breast cancer
ABC 7 News
1/1/2012

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

UChicago Medicine Highlights Research, Leadership, Clinical Advances at ASCO 2026June 11th, 2026
Rechallenging with Pembrolizumab After Immune-Related Adverse Events in Triple-Negative Breast Cancer: Clinical Considerations and Emerging PracticeSeptember 25th, 2025
New Chicago Breast Cancer Research Consortium Will Increase Access to Clinical TrialsSeptember 4th, 2025